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a b s t r a c t
Background: The effectiveness of the wearable cardioverter deﬁbrillator (WCD) therapy in early post-
myocardial infarction (MI) patients remains uncertain.
Methods: We analyzed the characteristics and outcomes of patients who received a WCD in the early
post-MI phase.
Results: Twenty-four patients were followed-up for 8 months (range, 4–16 months). Two patients (8.3%)
received appropriate shocks. Left ventricular ejection fraction improved after the WCD therapy (Po0.01).
Fourteen patients (58%) received an implantable cardioverter deﬁbrillator at the end of the follow-up
period.
Conclusion: Early post-MI patients at high risk of sudden cardiac death may beneﬁt from WCD therapy.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
The wearable cardioverter deﬁbrillator (WCD; Life Vest 4000,
Zoll, PA, USA) is an external deﬁbrillator vest that automatically
detects and treats ventricular tachyarrhythmias without bystander
assistance [1–3]. Patients with early post-myocardial infarction
(MI) are potentially at signiﬁcant risk of sudden cardiac death
(SCD). However, information for prescribing WCD to patients in
the early post-MI phase is limited [4]. This study describes a
single-center experience of the utility of WCD therapy in these
patients in Germany.
2. Materials and methods
This study included WCD patients with high risk of SCD but did
not meet the eligibility criteria for immediate implantation of an
implantable cardioverter deﬁbrillator (ICD). Current guidelines
endorse indications for WCD therapy [5]. Patients with low left
ventricular ejection fraction (LVEF; r35%) or therapy-refractory
nonsustained ventricular tachycardias are at high risk of SCD.
However, the guidelines recommend ICD implantation only after
waiting at least 40 days or 3 months, depending on whether the
patient had undergone revascularization or not. In patients who
experience lethal ventricular arrhythmia after MI, ICD implanta-
tion is considered after assessment of the efﬁcacies of revascular-
ization, catheter ablation, and anti-arrhythmic therapy. If these
therapies fail, ICD implantation is recommended.
We analyzed the characteristics and outcomes of patients with
ventricular tachyarrhythmia in the early post-MI phase who
received a WCD. All of the patients were followed up between
August 2010 and November 2014 at the University Hospital of Bonn,
Germany. Details of the WCD and the arrhythmia detection algo-
rithm were described elsewhere [1,2]. Variables were reported as
mean7standard deviation, median (25–75 percentiles), or n (%).
The patients' characteristics were compared by using the Fisher
exact test for categorical variables and the t test for continuous
variables. Statistical signiﬁcance was established at Po0.05.
3. Results
3.1. Characteristics and Outcomes of the WCD Patients
After obtaining written informed consent, 66 consecutive patients
in our hospital received WCD therapy, of whom 24 (36%) were in the
early post-MI phase and were followed up for 8 months (range, 4–16
months) (the period from the date of MI onset to the date of last
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follow-up). Table 1 shows the characteristics and outcomes of the
patients. The mean age of the patients was 69712 years, and 22 (92%)
of themweremale. Of the 24 patients, 10 (42%) had STelevation and 19
(79%) underwent acute revascularization. Eighteen patients received
PCI, and only 1 patient (primary indication) underwent coronary artery
bypass grafting surgery. Eleven patients (46%) used a WCD for primary
SCD prevention. Meanwhile, 13 patients (54%) used a WCD for
secondary SCD prevention after sustained ventricular tachycardia or
cardiopulmonary resuscitation. Of these patients, 12 (92%) experienced
lethal ventricular arrhythmia before or during revascularization. Only
1 patient (7.7%) had sustained ventricular tachycardia 7 days after MI.
The median time fromMI to the WCD prescriptionwas 10 days (range,
5–31 days). The median length of use was 33 days (20–67 days), and
the median daily WCD use was 23.1 h/day (range, 21.6–23.6 h/day).
One patient (4.2%) was excluded because of irregularities in device use.
LVEF improved after using a WCD (30% [range, 20–36%] vs. 35% [range,
25–40%], Po0.01). In 12 patients (50%), LVEF was 435%. In 8 patients
(33%), LVEF improved from r35% to 435%. None of the patients died
during the WCD therapy. However, 2 patients (8.3%) had a fatal
nonarrhythmic event within 3 months after MI.
3.2. WCD shock therapy
Two patients (8.3%) received shock therapy from the WCD.
First-shock success for ventricular ﬁbrillation (VF) was 100% (3/3).
One of the patients, who used a WCD for primary SCD prevention,
had 2 VF episodes within 6 days after MI onset. The second
patient, who used a WCD because of VF during MI, had VF again 15
days after MI onset. The LVEF of these patients was r35% before
using a WCD (29% and 34%). None of the patients experienced
inappropriate treatments.
3.3. ICD implantation after WCD therapy
An ICD was implanted in 14 patients (58%) at the end of the
follow-up period. Table 2 shows the relationship between serial
cardiac function and ICD implantation in all 13 patients indicated
for primary SCD prevention. Eleven patients (46%) used a WCD for
primary prevention, of whom 4 (36%) received an ICD because their
LVEFs remained at r35%. However, 2 patients (numbers 5 and 9)
refused to receive an ICD. Thirteen patients (54%) used a WCD for
secondary prevention, of whom 10 (77%) received an ICD.
4. Discussion
Currently, ICD therapy represents a cornerstone of cardiology
practice for reducing the incidence of SCD after MI [6–9]. However,
previous randomized trials [10,11] could not show a mortality
beneﬁt of early ICD implantation in post-MI patients. Hence, in
patients with LV dysfunction in acute MI, current guidelines in the
United States and Europe [5] recommend ICD implantation only
after waiting at least 40 days or 3 months, depending on whether
the patient had undergone revascularization or not. In this study,
the median time from MI to WCD prescription was 10 days (range,
5–31 days) and the median length of use was 33 days (range, 20–
67 days). Compared with the current guidelines, actual practice
uses the mean waiting period. A proportion of the post-MI
population eventually recovered LV function without further risk
of SCD (i.e., crossing the EF threshold of 35–40%). The present
study reveals that the median LVEF improved with WCD therapy
(30% [range, 20–36%] vs. 35% [range, 25–40%], Po0.01). Thus, ICD
implantation was prevented in 10 patients (42%). The use of WCD
contributed to the prevention of an unnecessary ICD implantation.
Inappropriate shock is rare, occurring in only 0–3% ofWCD patients
[12,13]. A WCD is a unique tool designed to avoid an unnecessary
shock therapy. If persistent arrhythmia is detected, the WCD notiﬁes
the patient via a responsiveness test, allowing a conscious patient to
prevent treatment by holding the Response buttons. Therefore,
education and medical information have been provided to patients
in order to optimize their understanding and acceptance of WCD
therapy. Most of our patients agreed that the device was easy to
handle after sufﬁcient training before receiving the device.
5. Conclusion
Patients in the early post-MI phase who are at high risk of SCD
may beneﬁt from a time-limited WCD therapy.
Table 1
Characteristics and outcomes of the WCD patients.
All patients (n¼24) Primary indication (n¼11) Secondary indication (n¼13) P value
Age (years) 69712 67711 7673 0.59
Male 22 (92) 9 (82) 13 (100) 0.20
ST-elevated MI 10 (42) 1 (9.1) 9 (69) 0.0045
Revascularized post-MI 19 (79) 9 (82) 10 (77) 1.0
Median time from MI to WCD prescription (days) 10 (5–31) 6 (4–20) 17 (7–38) 0.19
Median length of WCD use (days) 33 (20–67) 16 (29–56) 29 (15–67) 0.97
Median daily use of WCD (h/day) 23.1 (21.6–23.6) 22.8 (20.0–23.2) 23.3 (22.4–23.6) 0.23
LVEF before WCD therapy (%) 30 (20–36) 30 (18–34) 32 (20–38) 0.36
LVEF after WCD therapy (%) 35 (25–40) 33 (30–38) 43 (30–53) 0.26
WCD shock therapy 2 (8.3) 1 (9.1) 1 (7.7) 1.0
Deﬁbrillator implantation 14 (58) 4 (36) 10 (77) 0.095
The data are presented as mean7SD, number of patients (%), or median (25–75th percentile). WCD, wearable cardioverter deﬁbrillator; MI, myocardial infarction; LVEF, left
ventricular ejection fraction.
Table 2
Relationship between serial cardiac function and ICD implantation in patients
indicated for primary prevention of SCD.
Patient
no.
LVEF before WCD
therapy
LVEF after WCD
therapy
ICD
implantation
1 30 40 No
2 10 40 No
3 37 30 Yes
4 55 68 No
5 15 30 No (refuse)
6 35 35 No
7 30 33 Yes
8 15 21 Yes
9 29 25 No (refuse)
10 20 38 No
11 32 32 Yes
ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction;
WCD, wearable cardioverter deﬁbrillator; SCD, sudden cardiac death.
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